Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aytu Biopharma (AYTU) Restructuring Costs (2020 - 2024)

Aytu Biopharma (AYTU) has disclosed Restructuring Costs for 3 consecutive years, with $1.3 million as the latest value for Q4 2024.

  • Quarterly Restructuring Costs changed N/A to $1.3 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $1.3 million through Sep 2025, down 55.2% year-over-year, with the annual reading at $2.1 million for FY2025, 2.55% down from the prior year.
  • Restructuring Costs for Q4 2024 was $1.3 million at Aytu Biopharma, up from $784000.0 in the prior quarter.
  • The five-year high for Restructuring Costs was $2.9 million in Q1 2021, with the low at -$3.2 million in Q2 2021.
  • Average Restructuring Costs over 3 years is $709262.2, with a median of $814277.0 recorded in 2020.
  • Peak annual rise in Restructuring Costs hit 832.23% in 2021, while the deepest fall reached 494.34% in 2021.
  • Over 3 years, Restructuring Costs stood at $1.3 million in 2020, then crashed by 344.74% to -$3.2 million in 2021, then surged by 141.02% to $1.3 million in 2024.
  • According to Business Quant data, Restructuring Costs over the past three periods came in at $1.3 million, $784000.0, and $1.9 million for Q4 2024, Q3 2024, and Q2 2024 respectively.